Cargando…
Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer
OBJECTIVE: To explore the genetic changes in the progression of castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC) and the reason why these cancers resist existing therapies. METHODS: We employed our CRPC cell line microarray and other CRPC or NEPC datasets to scre...
Autores principales: | Wang, Qiong, Li, Zean, Yang, Jin, Peng, Shirong, Zhou, Qianghua, Yao, Kai, Cai, Wenli, Xie, Zhongqiu, Qin, Fujun, Li, Hui, Chen, Xu, Li, Kaiwen, Huang, Hai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Compuscript
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425180/ https://www.ncbi.nlm.nih.gov/pubmed/34591415 http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0550 |
Ejemplares similares
-
Topoisomerase II-binding protein 1 promotes the progression of prostate cancer via ATR-CHK1 signaling pathway
por: Li, Kaiwen, et al.
Publicado: (2020) -
Immune Cytolytic Activity as an Indicator of Immune Checkpoint Inhibitors Treatment for Prostate Cancer
por: Gao, Ze, et al.
Publicado: (2020) -
B7 score and T cell infiltration stratify immune status in prostate cancer
por: Zhou, Qianghua, et al.
Publicado: (2021) -
The metastatic promoter DEPDC1B induces epithelial‐mesenchymal transition and promotes prostate cancer cell proliferation via Rac1‐PAK1 signaling
por: Li, Zean, et al.
Publicado: (2020) -
GADD45B Is a Potential Diagnostic and Therapeutic Target Gene in Chemotherapy-Resistant Prostate Cancer
por: Wang, Qiong, et al.
Publicado: (2021)